title: Updated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.
abstract: Chemotherapy with improved effect in patients with metastatic pancreatic cancer has recently been established, launching a new era for patients with this very aggressive disease. FOLFIRINOX and gemcitabine plus nab-paclitaxel are different regimens, both capable of stabilizing the disease, thus increasing the number of patients who can reach second line and even third line of treatment. Concurrently, new windows of opportunity open for nutritional support and other therapeutic interventions, improving quality of life. Also pancreatic surgery has changed significantly during the latest years. Extended operations, including vascular/multivisceral resections are frequently performed in specialized centers, pushing borders of resectability. Potentially curative treatment including neoadjuvant and adjuvant chemotherapy is offered new patient groups. Translational research is the basis for the essential understanding of the ongoing development. Even thou biomarkers for clinical management of patients with periampullary tumors have almost been lacking, biomarker driven trials are now in progress. New insight is constantly made available for clinicians; one recent example is selection of patients for gemcitabine treatment based on the expression level of the human equilibrium nucleoside transporter 1. An example of new diagnostic tools is identification of early pancreatic cancer patients by a three-biomarker panel in urine: The proteins lymphatic vessel endothelial hyaluronan receptor 1, regenerating gene 1 alpha and translation elongation factor 1 alpha. Requirement of treatment guideline revisions is intensifying, as combined chemotherapy regimens result in unexpected advantages. The European Study Group for Pancreatic Cancer 4 trial outcome is an illustration: Addition of capecitabine in the adjuvant setting improved overall survival more than expected from the effect in advanced disease. Rapid implementation of new treatment options is mandatory when progress finally extends to patients with this serious disease.
authors.affiliation: Trond A Buanes, Department of Hepato-Pancreatico-Biliary Surgery, Oslo University Hospital, N-0424 Oslo, Norway.
authors.forename: Trond A
authors.initials: TA
authors.lastname: Buanes
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000473:pathology / Q000628:therapy* / Q000652:urine; D014670:Ampulla of Vater / Q000473:pathology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000652:urine; D017024:Chemotherapy, Adjuvant; D003138:Common Bile Duct Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy* / Q000652:urine; D020869:Gene Expression Profiling; D006801:Humans; D000072662:Margins of Excision; D020360:Neoadjuvant Therapy; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000473:pathology / Q000628:therapy* / Q000652:urine; D016577:Pancreaticoduodenectomy; D057285:Precision Medicine / Q000379:methods; D011788:Quality of Life; D057170:Translational Research, Biomedical; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor
keywords: Chemotherapy; Clinical outcome; Evidence-based medicine; Molecular expression profiling; Pancreatic cancer; Periampullary tumor; Prognostic markers; Survival